WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy 11 May 2017
Pfizer unveils ATLAS®, an interactive, user-friendly website that provides global antibiotic resistance surveillance data across 60 countries 21 April 2017
XELJANZ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis 27 March 2017
The Union for International Cancer Control and Pfizer announce next phase of global grants initiative supporting metastatic breast cancer patients 09 March 2017
Ronald E. Blaylock elected to Pfizer's Board of Directors 24 February 2017
Relationship expert teams up with Pfizer to address intimacy and relationship issues for people living with chronic diseases 10 February 2017
Pfizer reports fourth-quarter and full-year 2016 results 31 January 2017
Pfizer announces expansion of ASPIRE awards program for 2017 to include $5.5M in funding for breast and hematologic cancers 14 December 2016
IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery 02 December 2016
Pfizer's Prevenar 13® receives approval for use in infants and children in China 02 November 2016
Pfizer awarded grant to evaluate vaccine to protect newborns against group B Streptococcus infection 19 October 2016
Pfizer decides remaining one company best positions company to maximize future value creation 26 September 2016
Pfizer launches new "Moodivator" app to help support, encourage and motivate people with depression 14 September 2016
Pfizer appoints chief scientific officer for neuroscience research 08 September 2016
Pfizer to acquire small molecule anti-infective business from AstraZeneca 24 August 2016
Pfizer announces publication of new analysis showing long-term therapy with VYNDAQEL (tafamidis) slowed progression of rare neurodegenerative disease 12 August 2016
Pfizer aims to become industry leader in gene therapy with acquisition of Bamboo Therapeutics, Inc. 02 August 2016
Pfizer receives World Health Organization prequalification for multi-dose vial presentation of Prevenar 13® 19 July 2016
Merck and Pfizer initiate Phase III trial to evaluate Avelumab as first-line treatment for ovarian cancer 07 July 2016
Pfizer completes acquisition of Anacor 24 June 2016
  • Start
  • Prev
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer invests $43 billion to battle cancer

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.